TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9895419
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 control yoghurts daily)
Study: 3051991
Drug: Diltiazem (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (sustained-release preparation, titrated from 240 to 360 mg/day in a twice-daily regimen)
Study: 101315
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered sodium cromoglycate (400 mg to 600 mg, four times daily)
Study: 30614138
Drug: Low-flow induction
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow induction (Group L)
Study: 23537605
Drug: Community Treatment
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Treatment Orders (CTOs)
Study: 21817820
Drug: HES 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 130/0.4 (≤ 30 ml/kg) followed by crystalloid infusion
Study: 15234290
Drug: Deferred-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred-treatment group
Study: 15234290
Drug: Immediate-treatment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-treatment group
Study: 9741505
Drug: Time from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time from symptom onset to treatment
Study: 6348714
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg
Study: 3072354
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg plus codeine 60 mg
Study: 1378147
Drug: Carvedilol 50
Normalized name: carvedilol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 50 mg
Study: 21129866
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous bisphosphonates
Study: 19268266
Drug: Diosmectite (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmectite (6 g/day for children 1-12 months; 12 g/day for children 13-36 months)
Study: 17316925
Drug: WHO 17D-213/77
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO 17D-213/77 vaccine
Study: 17316925
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of yellow fever and measles-mumps-rubella vaccines
Study: 27838777
Drug: Auranofin 6
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin 6 mg orally on day #2 of the chemotherapy cycle (post-paclitaxel)
Study: 15579782
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg androstenedione t.i.d. for 28 days
Study: 2946277
Drug: 3 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 monthly doses of 2 micrograms vaccine mixed with adjuvant subcutaneously (Institut Pasteur Production‐Hevac B)
Study: 2946277
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 2 micrograms non‐adjuvated vaccine intradermally given 1 month apart
Study: 24387842
Drug: Novamin 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novamin 18 AAs (2 mL/kg/h)
Study: 24387842
Drug: Pethidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (0.5 mg/kg)
Study: 18496149
Drug: Tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1 mg/kg)
Study: 19631856
Drug: Treatment delivered
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment delivered after occurrence of dental trauma
Study: 17435407
Drug: Skin rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin rehabilitation massage therapy (SRMT) for 3 months
Study: 17435407
Drug: Skin rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin rehabilitation massage therapy (SRMT)
Study: 29923299
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg daily for 3 days
Study: 25372085
Drug: Rituximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (500 mg on days 0 and 14, and at months 6, 12, and 18)
Study: 25372085
Drug: Azathioprine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (daily until month 22)
Study: 20030435
Drug: Hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20 single-injection formulation
Study: 18930254
Drug: Lycopene supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene supplement
Study: 14654762
Drug: Diuretic-based regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic-based regimen (usually bendroflumethiazide)
Study: 14654762
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor regimen (usually lisinopril)
Study: 14654762
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (combined diuretic and ACE inhibitor)
Study: 11127968
Drug: Vitamin A;
Normalized name: Acai Palm/Amylase/Amyloglucosidase/Apple/Ascorbic Acid/Banana/Beet/Beta-Fructofuranosidase/Black Currant/Blackberry/Blueberry/Cellulase/Cherry/Cranberry/Cyanocobalamin/Elderberry/Folic Acid/Goji/Grape/Hemicellulase/Lactobacillus Acidophilus/Lemon/Lipase/Mango/Noni/Orange/Papaya/Peach/Pectinase/Phytase/Pineapple/Plum/Pomegranate/Protease/Prune/Pyridoxine/Raspberry/Strawberry/Vitamin A;Amylase/Amyloglucosidase/Barley Grass/Beet/Bell Pepper/Beta-Fructofuranosidase/Broccoli/Cabbage/Carrot/Cellulase/Collard Green/Couch Grass/Folic Acid/Garlic/Ginger Root/Hemicellulase/Kale/Kelp/Lipase/Maitake Mushroom/Oat Bran/Onion/Parsley/Pectinase/Phytase/Protease/Pumpkin/Selenium/Spinach/Spirulina/Sweet Potato/Tomato/Turmeric/Vitamin A/Vitamin E 50 MG-50 MCG-60 MCG-100 MILLION CFU-2.5 MG-375 MCG; 140 MCG-100 MCG-375 MCG-10 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A; specific dosage and duration not available
Study: 24368725
Drug: 3‐day intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐day intravenous infusion of creatine phosphate (CP) after PCI
Study: 23734858
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional behavioral treatment (NT) for 16 weeks
Study: 16584506
Drug: Cabergoline therapy
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline therapy (0.5-1 mg twice per week) for 12 weeks
Study: 11038977
Drug: Drugs for
Normalized name: DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for nourishing the kidney‐yin, invigorating blood circulation and removing blood stasis
Study: 11038977
Drug: Euglucon and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglucon and other routine drugs
Study: 26870801
Drug: Rotavirus vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccine
Study: 3948126
Drug: Rubidazone 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubidazone 450 mg/m2
Study: 3948126
Drug: Rubidazone 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubidazone 300 mg/m2
Study: 24531549
Drug: Buspirone (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (serotonin receptor type 1A agonist) prior to levodopa administration
Study: 24531549
Drug: Levodopa (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (identical doses)
Study: 18702965
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (rosuvastatin 10 or 20 mg, atorvastatin 10 or 20 mg, simvastatin 20 or 40 mg)
Study: 15936647
Drug: Black currant
Normalized name: Black currant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black currant seed oil (3 g/day)
Study: 15936647
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.8 g/day)
Study: 11228758
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) and Glibenclamide (G)
Study: 11228758
Drug: Proinsulin change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proinsulin change after therapy
Study: 8759264
Drug: Sublingual timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual timolol
Study: 1930769
Drug: Carbachol exposure
Normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbachol exposure (10 mg/mL) after nitrogen dioxide exposure
Study: 1930769
Drug: Carbachol exposure
Normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbachol exposure (10 mg/mL) after air exposure
Study: 6627695
Drug: Metoclopramide, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 30 mg daily
Study: 30113395
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) 6 µg
Study: 30113395
Drug: Phenylephrine (PE)
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine (PE) 100 µg
Study: 29764293
Drug: Biological educational
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological educational intervention
Study: 24666617
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (dAPT) - clopidogrel (75 mg) plus aspirin (300 mg)
Study: 24666617
Drug: Aspirin-monotherapy (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-monotherapy (300 mg)
Study: 24666617
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (dAPT)
Study: 9699192
Drug: Preparation intervention
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation intervention (health education sessions)
Study: 9699192
Drug: Preparation intervention
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation intervention
Study: 7908610
Drug: Bucindolol 200
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 200 mg/d (high dose)
Study: 7908610
Drug: Bucindolol 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 12.5 mg/d (low dose)
Study: 7908610
Drug: Bucindolol 50
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 50 mg/d (medium dose)
Study: 3171039
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for isolated systolic hypertension
Study: 21907780
Drug: ModraDoc001 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ModraDoc001 15 mg capsules
Study: 21907780
Drug: docetaxel premix
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel premix solution (TAXOTERE)
Study: 12642306
Drug: Single lyophilisate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single lyophilisate (204 mg)
Study: 12642306
Drug: Three conventional
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three conventional eye drops (40 ml fluorescein SE Thilo 0.17%)
Study: 10673700
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg LSF
Study: 10673700
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg LSF
Study: 9266139
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies to block TNF-alpha
Study: 10652641
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist
Study: 9266139
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies with monoclonal antibodies and long-acting rheumatic drugs (e.g., methotrexate)
Study: 8184764
Drug: Patients selected
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients selected for late ventricular enlargement (change in ED volume > 20 ml, n = 19)
Study: 3513801
Drug: Indomethacin, 25
Normalized name: Indomethacin, 25 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 25 mg, four times a day during therapy
Study: 3513801
Drug: Placebo, four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, four times a day during therapy
Study: 30088841
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation containing Lactobacillus, Bifidobacterium, and Streptococcus spp., 2 capsules daily for 14 days
Study: 30088841
Drug: Placebo, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily for 14 days
Study: 25802980
Drug: EPA (eicosapentaenoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (eicosapentaenoic acid) 1060 mg day(‐1)
Study: 25802980
Drug: DHA (docosahexaenoic
Normalized name: Atabex DHA (docosahexaenoic acid 250 MG / eicosapentaenoic acid 100 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (docosahexaenoic acid) 900 mg day(‐1)
Study: 22738908
Drug: Imagery Rehearsal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery Rehearsal Therapy
Study: 17137468
Drug: Early Treatment
Normalized name: Clearly It!
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Treatment
Study: 12070645
Drug: ACD anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACD anticoagulant (group A)
Study: 7705801
Drug: L‐alanyl‐L‐tyrosine (Ala‐Tyr)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐alanyl‐L‐tyrosine (Ala‐Tyr)
Study: 7705801
Drug: glycyl‐L‐tyrosine (Gly‐Tyr)
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycyl‐L‐tyrosine (Gly‐Tyr)
Study: 7705801
Drug: N‐acetyl‐L‐tyrosine (Nac‐Tyr)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐acetyl‐L‐tyrosine (Nac‐Tyr)
Study: 28478214
Drug: 15% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% carbamide peroxide gel in tray
Study: 23351409
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL low-calorie cranberry juice cocktail (CJC) per day for 4 weeks
Study: 23351409
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL placebo juice (PJ) per day for 4 weeks
Study: 12891223
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg daily)
Study: 15794388
Drug: LA 600
Normalized name: Stress Formula 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA 600 mg twice a day
Study: 15794388
Drug: LA 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA 1200 mg once a day
Study: 15794388
Drug: LA 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA 1200 mg twice a day
Study: 15794388
Drug: LA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA (all doses)
Study: 10713866
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Lem1 (natural compound from lemon oil)
Study: 8547043
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (pulsed tunable dye laser)
Study: 6255982
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of ACTH
Study: 26441156
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics
Study: 31575006
Drug: Cold pack
Normalized name: CVS Cold Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold pack (gel ice) applied postoperatively (Group 3)
Study: 17520860
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g x kg(‐1) NaHCO3
Study: 17520860
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g NaCl (placebo)
Study: 7521498
Drug: Aprotinin 7
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin 7 mg/kg until the end of perfusion
Study: 2631971
Drug: Biobehavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biobehavioral treatment (bed rest, compliance enhancement training, and individualized thermal biofeedback-assisted relaxation training)
Study: 70924
Drug: 7.1 mg
Normalized name: papain 77.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.1 mg potassium dichromate
Study: 31092077
Drug: Sequential embryo
Normalized name: human embryo tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential embryo transfer on day 3 and day 5
Study: 28761608
Drug: Having additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Having additional monthly income from family members
Study: 19732095
Drug: Spironolactone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (300 mg)
Study: 19549427
Drug: Loratadine/Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine/Montelukast (10 mg/10 mg once-daily)
Study: 19549427
Drug: Pseudoephedrine (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine (240 mg once-daily)
Study: 16442368
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg and 20 mg
Study: 8277150
Drug: Fluoxetine, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, 60 mg daily
Study: 24599529
Drug: AS02V with
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS02V with 10 or 30 μg PhtD-dPly
Study: 24599529
Drug: Alum with
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum with 10 or 30 μg PhtD-dPly
Study: 24176494
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide pneumococcal vaccine (23PPV)
Study: 22103985
Drug: Isokinetic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isokinetic training programme (3 times weekly, starting at 60% of average peak torque, increasing from 1 set to 10 sets over sessions)
Study: 18977178
Drug: Control patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patch (3.2 microg/cm² [0.04% capsaicin])
Study: 17124437
Drug: Intratympanic gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic gentamicin (40 mg/ml, 0.7 ml; n=24)
Study: 17124437
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (4 mg/ml, 0.7 ml; n=21)
Study: 12208583
Drug: Bosentan (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (125 mg twice a day)
Study: 3246246
Drug: Nicardipine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (0.2 mg over 10 min)
Study: 27259463
Drug: HDF‐IPIS with
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDF‐IPIS with [Na+] of 240 mmol L-1
Study: 27259463
Drug: HDF‐IPIS with
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDF‐IPIS with [Na+] of 500 mmol L-1
Study: 14728641
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment from a geriatric home hospitalization service (GHHS)
Study: 14728641
Drug: General medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: General medical ward treatment (GMW)
Study: 11527658
Drug: Fenofibrate plus
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate plus folic acid (10 mg every other day)
Study: 8381646
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir for 14 to 21 days (for primary TI‐CMV disease)
Study: 2893240
Drug: Flumazenil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.2 to 1.0 mg in anaesthesiology; 0.1 to 2.0 mg in intensive care)
Study: 2893240
Drug: Flumazenil (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (single dose)
Study: 2893240
Drug: Flumazenil (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (repeated low intravenous doses or infusion at 0.1 mg/hour)
Study: 31177714
Drug: Comprehensive rehabilitation
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive rehabilitation treatment of individualized exercise program
Study: 21596324
Drug: Pravastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin treatment (20 mg/day, n = 40)
Study: 21596324
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 40)
Study: 10637238
Drug: Chemotherapy (CAF:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CAF: cyclophosphamide, doxorubicin, and fluorouracil)
Study: 10637238
Drug: Chemohormonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemohormonal therapy (CAFTH: CAF plus tamoxifen and Halotestin)
Study: 10637238
Drug: Chemohormonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemohormonal therapy (CAFTH)
Study: 10637238
Drug: Chemotherapy (CAF)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CAF)
Study: 29215955
Drug: Trifluridine/tipiracil (TAS-102),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil (TAS-102), administered twice per day orally; 5 days on and 2 days off for 2 weeks, followed by 14 days off per cycle.
Study: 27681394
Drug: multi‐herbal mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: multi‐herbal mouth rinse, 15 ml twice a day
Study: 27681394
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine mouth rinse, 15 ml twice a day
Study: 27681394
Drug: essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: essential oil mouth rinse, 15 ml twice a day
Study: 27681394
Drug: 0.2% sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% sodium fluoride mouth rinse, twice a day